thromboprophylaxis

thromboprophylaxis

(throm″bō-prō″fĭ-lak′sĭs) [ thrombo- + prophylaxis]
Any preventive measure or medication that reduces the likelihood of the formation of blood clots.
thromboprophylactic (throm″bō-prō″fĭ-lak′tik), adjective
References in periodicals archive ?
Thromboprophylaxis is recommended and should be based on an assessment of the patient's underlying risks, treatment regimen, and clinical status.
Thromboprophylaxis in patients with acute spinal injuries: An evidencebased analysis.
Those studies examining the benefits of thromboprophylaxis in the setting of knee arthroscopy have all used low molecular weight heparin (LMWH) as the primary intervention with reductions in the risk of DVT ranging from 65% to 93%.
Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy.
Reprocessing of medical thromboprophylaxis stockings (MTPS).
Thromboprophylaxis has been shown to reduce PE-related death by 50%.
In other centres, this approach has improved compliance with thromboprophylaxis compliance and reduced prescription errors related to chemotherapy and total parenteral nutrition (Mitchell, Jones, Meguid, & Curtas, 1990; O'Connor, Adhikari, DeCaire, & Friedrich, 2009; Sano, Waddell, Solimando, Doulaveris, & Myhand, 2005).
Mr Williams said at the time he was not aware of the thromboprophylaxis risk assessment form but that had been "completely changed".
The understanding and interpretation of these factors may prove useful in identifying patients at high risk and implementing individualized practices of thromboprophylaxis, improving the survival and quality of life of cancer patients.
The duration of thromboprophylaxis remains unclear, but it is guided by risk factors such as active disease (e.
A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children.
Second, our recent observational study showed that omission of early thromboprophylaxis in patients who were considered to have contraindications to pharmacological thromboprophylaxis was associated with an increased risk of mortality in critically ill patients (11).